Regenerative Medicine of Raynham: A 2026 Patient Due-Diligence Guide
Introduction: Why Due Diligence Matters Before Choosing a Regenerative Medicine Provider
Non-surgical regenerative treatments have become a common topic of interest for people dealing with joint pain, sports injuries, and age-related mobility problems. Platelet-rich plasma (PRP), alpha-2-macroglobulin (A2M), and products often described as “stem-cell-adjacent” are now offered in clinics across Massachusetts. Franchise clinics have expanded at the same time, and they vary widely in how openly they explain who treats patients and what is being injected.
This guide is a neutral, third-party review written for due diligence. It does not promote any practice. Its focus is Regenerative Medicine of Raynham, a clinic in Southeastern Massachusetts, and it aims to do three things:
- Verify the practice’s legitimacy using publicly available records.
- Explain the provider-oversight model the clinic uses.
- Compare the clinic’s claims with current guidance from medical societies and regulators.
The sections below cover the legitimacy check, the care model, the evaluation process, the outcomes registry, and the scientific and regulatory context. The goal is to help readers decide whether booking a consultation makes sense for them.
Verifying the Practice: NAP, Formation, and Named Providers
Any due-diligence review should start with the basics: name, address, and phone number (often called NAP data). These details should match across independent sources.
- Legal business name: Regenerative Medicine Of Raynham LLC
- Registered address: 575 South Street West, Ste 2B, Raynham, MA 02767
- Phone: (774) 409-5055
Readers can check this information against the practice’s Better Business Bureau (BBB) profile and its Patch business listing for Raynham. Matching details across sources suggests a stable, physically located business rather than a short-lived operation.
According to its BBB profile, the business file was opened on February 11, 2022, and the practice is not BBB accredited. Accreditation is voluntary: a business has to apply for it and pay for it, so the lack of accreditation does not mean a practice is illegitimate or has unresolved complaints. Accreditation also says nothing about clinical quality. Patients should treat BBB status as one small piece of information, not a verdict either way.
The practice was established in 2019. Its roots in the community go back further, as the founder has more than 30 years of prior clinical work in the area. This history matters because it points to an established local practitioner expanding his services, not a pop-up clinic that opened to capitalize on regenerative medicine trends.
Who Is Behind the Practice? Founder and Provider Backgrounds
Dr. Brian Petrie, DC, is the founder. He is a chiropractor with a long local practice history. His interest in regenerative medicine, functional medicine, and healthy aging is also personal; he has described injuries built up over years of dirt biking and snowboarding, along with a motor vehicle accident.
This background helps explain the clinic’s focus, but readers should keep its limits in mind. A founder’s own recovery story, however sincere, is not clinical evidence that a treatment works. Judgments about efficacy should rest on research and an individual medical evaluation.
Melissa Teixeira Palmer, DNP, NP-C, is a board-certified nurse practitioner with a Doctor of Nursing Practice degree. Within her licensed scope of practice, she performs medical evaluations and procedures. In practical terms, she is the licensed medical provider responsible for the clinical work tied to injection-based care.
David Cunningham, MD, serves as Medical Director. The clinic describes his role as medical oversight, protocol review, and clinical consultation. These are specific, named duties, which sets the role apart from a figurehead title that simply attaches a physician’s name to a clinic.
The Collaborative Physician-Oversight Model Explained
A collaborative practice model combines providers with different licenses so that each works within their legal scope. In this setting, a licensed medical provider (a nurse practitioner or a physician) performs or directly supervises injections, while a chiropractor provides complementary care such as functional medicine, physical modalities, and lifestyle support.
TopDoctor Magazine’s reporting on this practice described collaborative models as “the common legal and clinical solution” for regenerative clinics. The structure helps ensure that procedures involving needles and biologic products are handled by people licensed to perform them.
At Regenerative Medicine of Raynham, the roles are defined as follows:
| Team Member | Credential | Stated Role |
|---|---|---|
| Dr. Brian Petrie | DC | Chiropractic and functional medicine care |
| Melissa Teixeira Palmer | DNP, NP-C | Medical evaluation and procedures within professional scope |
| David Cunningham | MD | Medical oversight, protocol review, clinical consultation |
Why This Model Matters: Transparency vs. Franchise Ambiguity
The regenerative medicine market in Massachusetts has grown more crowded. Franchise chains such as QC Kinetix run several locations in the state, including Boston, Weymouth, Lowell, Springfield, and Lawrence, all under one centralized brand. Large-scale models like this can make it harder for patients to see who is actually providing their care.
Independent reporting has raised this concern directly. A 2024 review of QC Kinetix published on The Niche (ipscell.com) said it was unclear which providers perform procedures. It also noted “the apparent running of some clinics without physicians there full-time” and called both issues “concerning.” That critique applies to one chain, but the question it raises is relevant to every clinic.
Before any procedure, patients should ask plainly: “Who performs the injection, and what is their license and training?” A clear, specific answer that names the provider and states the credential is a good sign. A vague answer is a reason to ask more questions.
Transparency about which named provider performs which role should be a core test when evaluating any regenerative medicine clinic. Regenerative Medicine of Raynham names its providers and their roles publicly, which meets this test on paper. Patients should still confirm during a visit that the arrangement works as described.
What Treatments Does the Practice Offer?
The clinic markets a wide range of non-surgical modalities. Each is described below by what it is intended to address. None of these descriptions should be read as a promise of results.
- Platelet-rich plasma (PRP): A concentrate made from the patient’s own blood and injected into joints or soft tissue. It is intended to support healing and reduce pain, most often in conditions like knee osteoarthritis.
- Alpha-2-macroglobulin (A2M): A blood-derived protein concentrate used with the aim of slowing enzymes linked to cartilage breakdown in arthritic joints.
- Shockwave therapy: Acoustic waves applied to tissue. It is typically used for tendon problems and chronic soft-tissue pain.
- Laser therapy: Low-level light applied to tissue with the goal of reducing pain and inflammation.
- Pulsed electromagnetic field (PEMF) therapy: Electromagnetic fields applied to the body. It is often marketed for pain relief and tissue recovery.
- Spinal and knee decompression: Mechanical techniques meant to ease pressure on joints or spinal structures.
- Metabolic and functional-medicine support: Care focused on metabolic health, inflammation, and lifestyle factors that may affect joint health and aging.
The practice also advertises allogeneic Wharton’s Jelly-derived biologic injection products as part of individualized non-surgical plans for joint function and mobility. “Allogeneic” means the material comes from a donor rather than the patient. Wharton’s Jelly is the connective tissue found in the umbilical cord.
An important caveat: these modalities do not all have the same level of clinical evidence or the same regulatory status. Some have meaningful research behind them, others have limited data, and some biologic products sit in a gray area from a regulatory standpoint. These differences are covered in the evidence section below.
The Evaluation-First Process: What Happens Before Any Procedure
According to the practice, care starts with a thorough evaluation before any procedure is recommended. The evaluation includes:
- Health history
- Previous treatments
- Imaging
- Current function
- Personal goals
Evaluating patients before treating them is widely seen as a patient-safety best practice in musculoskeletal and regenerative medicine. Joint pain has many possible causes: arthritis, tendon injuries, nerve problems, referred pain, and systemic inflammatory conditions can all look alike at first. A careful assessment helps match the treatment to the actual problem.
This step also lets providers screen out patients who are not good candidates. A person might have advanced joint damage that is unlikely to respond to injections, a medical condition that rules out certain procedures, or symptoms that need further workup (such as testing for infection or inflammatory disease) before any regenerative treatment is considered. Responsible clinics should be willing to say “this isn’t right for you.”
Patients should confirm during a consultation that the evaluation is substantive. A real evaluation involves reviewing imaging, doing a hands-on functional assessment, and discussing goals and expectations. A short intake form followed by a treatment package recommendation does not meet that standard.
The IRB-Backed Outcomes Registry: What It Means for Patient Safety
With patient consent, Regenerative Medicine of Raynham takes part in an observational outcomes registry that operates under Institutional Review Board (IRB) oversight.
An IRB is an independent committee that reviews research involving people. It checks that studies are ethical, that participants give informed consent, that privacy is protected, and that the methods are sound. IRB involvement adds accountability even when data collection is purely observational, meaning patients receive normal care and their results are recorded rather than assigned to experimental groups.
The registry’s stated purpose is to track meaningful changes in pain, function, and quality of life over time. This kind of systematic follow-up is more rigorous than relying on testimonials.
Readers should understand what a registry is and what it is not. An observational registry is not a clinical trial. It has no control group, no placebo comparison, and no randomization. It records real-world outcomes, but it cannot show that a treatment caused an improvement. It also does not mean the FDA has approved the treatment.
Useful questions for patients include:
- Is participation fully optional, and does declining affect my care in any way?
- How is my data stored, anonymized, and used?
- Who runs the registry, and which IRB oversees it?
- How are results reported, published, or audited?
Contextualizing Clinic Claims Against Current Medical Evidence
The evidence for PRP in knee osteoarthritis is mixed. A 2025 narrative review of 40 studies, published in the National Library of Medicine’s PMC database, found that PRP injections, especially leukocyte-poor PRP, showed better pain relief and functional improvement than hyaluronic acid and corticosteroids. The benefit was clearest in patients with mild to moderate knee osteoarthritis.
Major specialty societies remain cautious. As noted in a registered clinical trial record on ClinicalTrials.gov, the American College of Rheumatology (ACR), the Osteoarthritis Research Society International (OARSI), and the American Academy of Orthopaedic Surgeons (AAOS) do not currently recommend PRP for symptomatic knee OA. They cite a lack of high-quality, placebo-controlled evidence.
These two positions do not necessarily conflict. Research findings and formal society guidelines tend to change at different speeds. Guideline committees often wait for large, well-controlled trials before changing recommendations, while new studies can show promising trends earlier. Patients should understand both sides before deciding.
The regulatory picture is especially important for biologic products. The FDA continues to warn patients and consumers to avoid unapproved products made from human cells or tissues that are marketed for a wide range of diseases or conditions. The agency has documented serious harms linked to some of these products.
The only stem cell products currently FDA-approved in the United States are blood-forming stem cells derived from umbilical cord blood, which are used for certain blood and immune disorders. This means most injectable orthobiologics sold by regenerative clinics, including Wharton’s Jelly-derived products, are not FDA-approved drugs. PRP is regulated differently because it is processed from the patient’s own blood using cleared devices.
Patients should ask any clinic directly about the regulatory status of each product offered to them. Marketing terms such as “stem cell therapy” deserve informed skepticism. Many umbilical tissue products contain few or no living stem cells, and calling them “stem cell” treatments can create expectations the evidence does not support.
A Practical Checklist: Questions to Ask Before Booking a Consultation
Patients can use these questions with Regenerative Medicine of Raynham or with any other regenerative medicine provider:
- Who will personally perform my procedure, and what is their license (MD, NP, DC)?
- What does the initial evaluation include, and will imaging or prior records be reviewed?
- Is participation in the outcomes registry optional, and how is my data handled?
- What is the regulatory status of the specific biologic or injectable product being recommended?
- How does the recommended treatment align with (or differ from) current ACR, OARSI, and AAOS guidance for my specific condition?
- What realistic outcomes, timelines, and limitations should I expect, based on current evidence rather than marketing claims?
A trustworthy provider should welcome these questions and answer them clearly.
Conclusion: Weighing Transparency, Oversight, and Evidence
Public records confirm that Regenerative Medicine Of Raynham LLC is a legally registered practice at a consistent, checkable address. It is rooted in a local clinical career that spans more than three decades. It names its credentialed providers and assigns each a specific role within a collaborative oversight model: a chiropractor, a doctorally prepared nurse practitioner, and a physician medical director.
The evaluation-first process and the IRB-backed outcomes registry are real patient-safety safeguards. Neither is absolute. An evaluation is only as good as how thoroughly it is done, and a registry records outcomes without proving that a treatment works.
The practice’s main offerings, especially PRP and biologic injections, sit in an area where new evidence looks promising but professional societies still urge caution. Regulatory status also differs significantly from one product to another.
The checklist and context in this guide apply to any regenerative medicine provider, not only this one. Based on the available records, this practice is legitimate and open about its structure. Patients should still bring informed, evidence-based questions to any consultation.
Next Steps for Patients Considering a Consultation
- Contact the practice directly at (774) 409-5055 or visit 575 South Street West, Ste 2B, Raynham, MA 02767, and ask due-diligence questions before scheduling.
- Ask for clear answers, in writing or during the consultation, about who provides each part of care, what the evaluation covers, and the regulatory status of any recommended product.
- Get a second opinion from a primary care physician or orthopedic specialist on whether regenerative treatment is appropriate for the specific diagnosis.
- Base the decision on informed judgment, not marketing claims, before going ahead with any non-surgical joint-pain treatment.
